McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
GAITHERSBURG, Md., Dec. 16, 2016 -- OpGen, Inc. (NASDAQ:OPGN) announces that during the fourth quarter of 2016 it has issued approximately 3.6 million shares of its common stock under its previously announced “at the market offering” program, resulting in aggregate net proceeds to the Company of approximately $4.6 million. The proceeds will be used to support the company’s research, development and manufacturing of product candidates, and for other general corporate purposes.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
OpGen Contact: Michael Farmer Director, Marketing 240-813-1284 [email protected] [email protected] OpGen Investor and Media Contact: MacDougall Biomedical Communications Cammy Duong 781-591-3443 [email protected]
